Hilo, formerly Aktiia, has secured CHF 34M in Series B funding to advance its continuous blood pressure monitoring technology. Founded in 2018, the Swiss company aims to impact 100 million lives by 2032. With 15 years of innovative research behind its technology, Hilo transforms traditional blood pressure management by enabling frequent, cuffless measurements using new methods. The recent funding will support the expansion of its technology, partnerships with healthcare entities, and team growth, focusing on better health management solutions.
Hilo's revolutionary continuous blood pressure monitor aims to empower 100 million people by 2032 with a new level of personal health management.
Following major advancements in hypertension management, Hilo leverages 15 years of research to redefine how blood pressure is monitored and managed.
Collection
[
|
...
]